Fluoroquinolones Resistance (Universal)

A universal stool resistance screen looks for selected bacterial genes linked to reduced sensitivity to antibiotics. Finding one does not establish that an infection you have, or might develop later, will resist treatment. The result can describe part of your gut's resistance-gene reservoir, but its value for choosing antibiotics or preventing infections has not been established for this particular assay.

What This Marker Represents

The laboratory lists qnrA, qnrB, and qnrS1 under the universal fluoroquinolone marker. "Universal" here is a laboratory category meaning the result is not tied to one named organism. It does not mean complete coverage: at least six qnr gene families have been described, and this panel targets a subset of them. These are also different targets from the gyrA and gyrB mutations in the laboratory's H. pylori-specific resistance section. The universal result cannot identify which bacterial species carries a detected gene.

This assay uses qPCR to amplify selected DNA sequences from a collected stool sample. Although qPCR can be used to estimate DNA quantities, the laboratory reports this resistance marker as positive or negative, with individual targets marked present or absent. It does not provide a resistance level to optimize.

For prevention screening, this remains an exploratory marker. Studies of resistance genes in gut communities support its biological relevance, but there are no validated personal risk estimates or treatment targets for this universal result.

How These Genes Affect Antibiotics

Fluoroquinolones interfere with bacterial enzymes needed to copy and maintain DNA. Laboratory experiments show that Qnr proteins can protect these enzymes from the drugs. The resulting reduction in susceptibility is often modest and may not cross the thresholds laboratories use to call an organism resistant. Additional resistance mechanisms usually determine whether an organism is classified as resistant in clinical testing.

Many qnr genes occur on plasmids. These are pieces of DNA that bacteria can transfer to one another, sometimes across species. Some plasmids carry resistance genes for several antibiotic families, so one drug can favor bacteria that also carry resistance to another. Detecting several genes in a mixed stool sample does not establish that they occupy the same plasmid or organism.

Why H. pylori Studies Describe a Different Test

H. pylori-specific resistance assays connect a mutation to the stomach bacterium being treated. In one clinical evaluation, a stool PCR kit targeting H. pylori gyrA mutations showed about 89% overall agreement with culture-based fluoroquinolone susceptibility testing, with roughly 87% agreement on resistant results and 91% on susceptible ones. That is evidence for that organism-specific kit, not a performance estimate for this universal qnr screen, and it does not validate any other laboratory's H. pylori assay simply because both look at gyrA. The two results cannot be substituted for each other.

Gut Carriage and Infection Risk

Some gut bacteria can later cause infections elsewhere. In a prospective study of men undergoing transrectal prostate biopsy, fluoroquinolone-resistant E. coli detected by culture was associated with serious infection afterward. The study measured the behavior of cultured bacteria, not the universal qnr result.

Research in stem cell transplant recipients found that carrying resistant Enterobacterales in the gut was associated with bloodstream infection, and that expansion of these bacteria sometimes preceded infection. Enterobacterales include E. coli and Klebsiella. Among those already colonized, though, how densely the bacteria were carried and how the rest of the microbial community looked did not distinguish who went on to develop infection. That study used stool cultures and bacterial-community sequencing in a highly vulnerable population. Its findings do not establish how much infection risk a positive universal gene screen carries for an otherwise healthy person.

What the Longevity Research Shows

The FINRISK study sequenced stool from 7,095 adults and linked the results to health records over 17 years. Higher total antibiotic-resistance gene abundance was associated with higher death rates after adjustment for several other risk factors. The measurement covered the broader collection of resistance genes in the gut, often called the resistome. It was not this targeted qPCR result, and the association does not establish that resistance genes caused the deaths or that lowering this marker would extend your life.

When Results Can Be Misleading

• Limited target coverage: this marker covers a subset of qnr gene families, and resistance can also arise through mutations in drug targets, altered drug entry, drug export, and other genes outside the panel. A negative result cannot establish susceptibility to ciprofloxacin, levofloxacin, or the entire drug class.
• Gene presence versus drug response: a detected gene may reduce susceptibility without making a particular bacterium clinically resistant. The organism, drug, gene activity, and other resistance mechanisms affect the outcome.
• DNA versus living bacteria: ordinary DNA-based qPCR can detect DNA from dead bacteria. A positive result alone does not prove persistent colonization by living bacteria.
• Stool processing: substances in stool can inhibit PCR, and how DNA is recovered, sample quality, and small amounts of target DNA can affect detection. Results from different laboratories or target sets are not interchangeable.
• Changes around sampling: antibiotics and travel can change which genes are detectable. Such changes can be biological, while intermittent detection can also reflect sampling and detection limits. One negative sample does not prove that a previously detected gene has disappeared.

How Results Can Change

This is a changing feature of your microbial community. In small studies, qnr genes sometimes remained detectable for weeks or months and sometimes appeared intermittently. Repeated results can document detection over time, but switching from positive to negative has not been validated as a measure of better health or lower infection risk.